Fig. 1.

Wy-14643 protects against D-GalN/LPS-induced liver injury and suppresses hepatocyte apoptosis. Male C57BL/6 mice were injected intraperitoneally with Wy-14643 (6 mg/kg) or vehicle (DMSO) 2 h prior to D-GalN (700 mg/kg) and LPS (10 μg/kg) exposure (n=12/group). The control mice were pre-treated with vehicle (DMSO) 2 h before PBS injection (n=10). One group of mice were euthanized with chloral hydrate (1.0 g/kg) 6 h after D-GalN/LPS treatment, and the liver and serum samples were collected for analysis. (A) In a second group of mice, the survival rate was analyzed in D-GalN/LPS-treated mice and Wy/D-GalN/LPS-treated mice up to 24 h after D-GalN/LPS injection. (n=10/group). (B) Representative livers and H&E staining of liver sections in control mice, D-GalN/LPS-treated mice, and Wy/D-GalN/LPS-treated mice. (C) Serum levels of ALT and AST from the three treatment groups. (D) TUNEL staining images from the three treatment groups. A representative experiment is shown. Original magnification 200×. (E) The levels of total caspase-3, cleaved caspase-3 and β-actin were measured by western blotting for the three treatment groups. A representative blot from two samples of every group is shown. Densitometry analysis of protein levels was performed for each sample. Data in C-E represented as means±s.d.